Sugi Predict

Sugi Predict / Compounds / SCHEMBL14217299

SCHEMBL14217299

SCHEMBL14217299

Cc1ccc(B2OC(C)(C)C(C)(C)O2)cc1C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 13/20 0.50
▸ LIPG Q9Y5X9 13/20 0.50
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ CA9 Q16790 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA3 P07451 1/20 0.42
▸ CA4 P22748 1/20 0.42
▸ CA6 P23280 1/20 0.42
▸ CA5A P35218 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ CA5B Q9Y2D0 1/20 0.42
▸ F11 P03951 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.40
▸ CSF1R P07333 1/20 0.39
▸ ESR2 Q92731 1/20 0.38
▸ HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28503429 0.89 CA1 (0.43) LPLLIPGCA1CA2CA9
SCHEMBL4426022 0.86 LPL (0.46) LPLLIPGCA1CA2CA9
SCHEMBL60127 0.84 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL4425474 0.84 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL19414434 0.84 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL30622816 0.84 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL17421143 0.84 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL14616470 0.82 LPL (0.53) LPLLIPGCA1CA2CA9
SCHEMBL31531362 0.82 LPL (0.46) LPLLIPGCA1CA2CA9
SCHEMBL32663644 0.82 LPL (0.46) LPLLIPGCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025073792-A1 WRN INHIBITORY COMPOUNDS FORX THERAPEUTICS AG (CH) 2025-04-10 — — WO disclosed
CN-117069728-A PI4KIII beta inhibitors 葛兰素史克知识产权开发有限公司 2023-11-17 — — CN disclosed
US-20230309378-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-09-28 — — US disclosed
US-11711968-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-07-25 — — US disclosed
CN-116171280-A Casein kinase 1 delta modulators 詹森药业有限公司 2023-05-26 — — CN disclosed
US-20230151017-A1 THERAPEUTIC AGENTS TARGETING GPR35 PROMETHEUS BIOSCIENCES, INC. 2023-05-18 — — US disclosed
CN-111868063-A PI4KIII beta inhibitors 葛兰素史克知识产权开发有限公司 2020-10-30 — — CN disclosed
US-10647733-B2 Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations THE UNIVERSITY OF CHICAGO (US) 2020-05-12 — — US disclosed
WO-2019141694-A1 PI4KIIIBETA INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-25 — — WO disclosed
US-20180102487-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2018-04-12 — — US disclosed
US-20160228442-A1 NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2016-08-11 — — US disclosed
US-9328118-B2 Nitrogen-containing bicyclic aromatic heterocyclic compound ASTELLAS PHARMA INC. (JP) 2016-05-03 — — US disclosed
WO-2015082592-A2 METHOD FOR PREPARING AMINOARYLBORANE COMPOUNDS OR DERIVATIVES THEREOF Universite de Bordeaux (FR) 2015-06-11 — — WO disclosed
WO-2015082592-A2 METHOD FOR PREPARING AMINOARYLBORANE COMPOUNDS OR DERIVATIVES THEREOF Universite de Bordeaux (FR) 2015-06-11 — — WO disclosed
EP-2881398-A1 Method for preparing aminoarylborane compounds or derivatives thereof Université de Bordeaux I (FR) 2015-06-10 — — EP disclosed
EP-2881398-A1 Method for preparing aminoarylborane compounds or derivatives thereof Université de Bordeaux I (FR) 2015-06-10 — — EP disclosed
US-20150126488-A1 NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC (JP) 2015-05-07 — — US disclosed
US-8507683-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-13 — — US disclosed
US-20120309770-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2012-12-06 — — US disclosed
US-20070116984-A1 SPIRO-COMPOUND FOR ELECTROLUMINESCENT DISPLAY DEVICE AND ELECTROLUMINESCENT DISPLAY DEVICE COMPRISING THE SAME DOOSAN CORPORATION (KR) 2007-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647733-B2 Metal-organic frameworks containing nitrogen-donor ligands for efficient catalytic organic transformations NCLN, MDH1, NNMT LPL 4013/4885LIPG 3849/4885CA1 1109/4885
US-11711968-B2 Organic electroluminescent materials and devices OCIAD1, LMNB1, RPS8 LPL 1350/4885LIPG 1420/4885CA1 2678/4885
US-20120309770-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 LPL 997/4885LIPG 1001/4885CA1 4243/4885
US-20180102487-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, LMNB1, RPS8 LPL 1350/4885LIPG 1420/4885CA1 2678/4885
US-20160228442-A1 NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND CTSS, CTSV, CTSB LPL 1651/4885LIPG 1043/4885CA1 572/4885
US-20230151017-A1 THERAPEUTIC AGENTS TARGETING GPR35 GPR35, GPR68, GPR65 LPL 802/4885LIPG 455/4885CA1 4783/4885
US-20150126488-A1 NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND CTSS, CTSV, CTSB LPL 1825/4885LIPG 981/4885CA1 381/4885
US-20230309378-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, LMNB1, RPS8 LPL 1350/4885LIPG 1420/4885CA1 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.